Ascierto, Paolo Antonio https://orcid.org/0000-0002-8322-475X
Del Vecchio, Michele
Mackiewicz, Andrzej
Robert, Caroline
Chiarion-Sileni, Vanna
Arance, Ana
Lebbé, Céleste
Svane, Inge Marie
McNeil, Catriona
Rutkowski, Piotr https://orcid.org/0000-0002-8920-5429
Loquai, Carmen
Mortier, Laurent
Hamid, Omid
Bastholt, Lars
Dreno, Brigitte
Schadendorf, Dirk
Garbe, Claus
Nyakas, Marta
Grob, Jean-Jacques
Thomas, Luc
Liszkay, Gabriella
Smylie, Michael
Hoeller, Christoph
Ferraresi, Virginia
Grange, Florent
Gutzmer, Ralf
Pikiel, Joanna
Hosein, Fareeda
Simsek, Burcin
Maio, Michele
Clinical trials referenced in this document:
Documents that mention this clinical trial
Cutaneous melanoma
https://doi.org/10.1016/s0140-6736(13)60802-8
Overall survival at 5 years of follow-up in a phase III trial comparing ipilimumab 10 mg/kg with 3 mg/kg in patients with advanced melanoma
https://doi.org/10.1136/jitc-2019-000391
Documents that mention this clinical trial
592 Phase 1/2a study of the novel nonfucosylated anti–CTLA-4 monoclonal antibody BMS-986218 ± nivolumab in advanced solid tumors: part 1 results
https://doi.org/10.1136/jitc-2022-sitc2022.0592
Overall survival at 5 years of follow-up in a phase III trial comparing ipilimumab 10 mg/kg with 3 mg/kg in patients with advanced melanoma
https://doi.org/10.1136/jitc-2019-000391
393 First-in-human phase 1/2a study of the novel nonfucosylated anti–CTLA-4 monoclonal antibody BMS-986218 ± nivolumab in advanced solid tumors: initial phase 1 results
https://doi.org/10.1136/jitc-2020-sitc2020.0393
Documents that mention this clinical trial
<i>CTLA4</i> promoter hypomethylation is a negative prognostic biomarker at initial diagnosis but predicts response and favorable outcome to anti-PD-1 based immunotherapy in clear cell renal cell carcinoma
https://doi.org/10.1136/jitc-2021-002949
Overall survival at 5 years of follow-up in a phase III trial comparing ipilimumab 10 mg/kg with 3 mg/kg in patients with advanced melanoma
https://doi.org/10.1136/jitc-2019-000391
Funding for this research was provided by:
This work was supported by Bristol-Myers Squibb (no grant number is applicable).